Open AccessImmunization with a Live Attenuated H7N9 Influenza Vaccine Protects Mice against Lethal Challenge
Author(s) -
Xiaolan Yang,
Jingjing Zhao,
Cheng Wang,
Yueqiang Duan,
Zhongpeng Zhao,
Rui Chen,
Liangyan Zhang,
Xing Li,
Lai Chen,
Shaogeng Zhang,
Xiliang Wang,
Peng Yang
Publication year - 2015
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0123659
Subject(s) - virology , attenuated vaccine , neuraminidase , hemagglutinin (influenza) , virus , biology , influenza a virus , immunization , nasal administration , viral replication , influenza vaccine , immune system , live attenuated influenza vaccine , microbiology and biotechnology , immunology , gene , virulence , genetics
The emergence of severe cases of human influenza A (H7N9) viral infection in China in the spring of 2003 resulted in a global effort to rapidly develop an effective candidate vaccine. In this study, a cold-adapted (ca), live attenuated monovalent reassortant influenza H7N9 virus (Ah01/AA ca) was generated using reverse genetics that contained hemagglutinin (HA) and neuraminidase (NA) genes from a 2013 pandemic A H7N9 isolate, A/Anhui/01/2013 virus (Ah01/H7N9); the remaining six backbone genes derived from the cold-adapted influenza H2N2 A/Ann Arbor/6/60 virus (AA virus). Ah01/AA ca virus exhibited temperature sensitivity (ts), ca, and attenuation (att) phenotypes. Intranasal immunization of female BALB/c mice with Ah01/AA ca twice at a 2-week interval induced robust humoral, mucosal, and cell-mediated immune responses in a dose-dependent manner. Furthermore, the candidate Ah01/AA ca virus was immunogenic and offered partial or complete protection of mice against a lethal challenge by the live 2013 influenza A H7N9 (A/Anhui/01/2013). Protection was demonstrated by the inhibition of viral replication and the attenuation of histopathological changes in the challenged mouse lung. Taken together, these data support the further evaluation of this Ah01/AA ca candidate vaccine in primates.